This analytic tool examines economic aspects of BluePath Solutions' Product cell administration and adverse event management in the inpatient and hospital outpatient settings from the provider perspective. The resulting output allows a hospital or health system to evaluate their Product cell therapy eligible population and assess the cost and reimbursement implications across sites of administration, by payer type, and by user-defined Product cell therapy cost and safety profiles for Product A and Product B.
The resource estimates several site-specific economic facets, including:
Costs to the
Provider
Costs of treating a patient with a Product therapy may include hospital room and board, cell transportation, storage, preparation, and administration, and adverse event management.
Reimbursement to the provider
Reimbursement varies by payer type; this tool includes Commercial, Medicare FFS, and Medicare Advantage to provide variety and coverage while remaining straightforward.
Patient cost share responsibility
Patients' cost sharing varies by care setting, payer type, and services received. This tool estimates patient cost sharing for Product therapy, including preparation and administration.